Atara Biotherapeutics Profit Margin

Atara Biotherapeutics (ATRA) currently reports a profit margin of -48.09% as of March 2026. That compares with -15.4% in the prior-year period — down 212.3% year over year. That is below the Healthcare sector average of 15.52%. Use the charts on this page to explore Atara Biotherapeutics's profit margin history and peer comparisons.

Atara Biotherapeutics's profit margin decreased from -15.4% to -48.09% — a 212.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Atara Biotherapeutics's profit margin of -48.09% is lower than the Healthcare sector average of 15.52%. That is roughly 409.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Atara Biotherapeutics's current -48.09% should be judged against Healthcare norms (sector average: 15.52%) and against ATRA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -48.09%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.52%. From there, open related valuation or income-statement pages for Atara Biotherapeutics, and consider following ATRA for alerts when major investors trade the stock.